NovaBay Expands Global Ophthalmology Study of Pink Eye to India
03 janv. 2013 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
Phase 2b BAYnovation Study for the Treatment of Viral Conjunctivitis Includes 60 Clinical Sites Worldwide
EMERYVILLE, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc....
NovaBay Pharmaceuticals to Present at Biotech Showcase 2013
19 déc. 2012 08h00 HE
|
NovaBay Pharmaceuticals, Inc.
Live Webcast Scheduled for January 8, 2013 at 2:45 pm (PST)
EMERYVILLE, Calif., Dec. 19, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company...
NovaBay Pharmaceuticals Provides Business Update and 2013 Outlook
13 déc. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
Recent $7 Million Financing to Accelerate and Expand Clinical Trials
Steady Progress Across Four Business Units:
Ophthalmology
Viral conjunctivitis (unmet medical need)
Financing...
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
06 déc. 2012 08h55 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 6, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
05 déc. 2012 16h06 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 5, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals to Present at LD Micro Conference
28 nov. 2012 08h00 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 28, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals Receives Additional $1.5 Million Equity Funding from Pioneer Pharma Co.
05 nov. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
This Completes the First $2.5 Million Tranche of a Potential Total Investment of $5.5 Million
EMERYVILLE, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY),...
NovaBay Pharmaceuticals Provides Third Quarter 2012 Financial Results
01 nov. 2012 06h19 HE
|
NovaBay Pharmaceuticals, Inc.
Enrollment Continues to Advance in Three Phase 2b Clinical Trials for Conjunctivitis, Impetigo and UCBE
Recent Highlights
Global Phase 2b clinical study of lead Aganocide® NVC-422 for...
NovaBay Pharmaceuticals to Present at Lazard Capital Markets 9th Annual Healthcare Conference
31 oct. 2012 08h00 HE
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals (NBY) Receives $2.6 Million From Partner Galderma
26 sept. 2012 07h30 HE
|
NovaBay Pharmaceuticals, Inc.
Marks Advancement of Aganocide® NVC-422 Clinical Program for Impetigo Treatment
EMERYVILLE, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a...